These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36317532)

  • 1. The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
    Doggrell SA
    Expert Opin Biol Ther; 2022 Nov; 22(11):1339-1343. PubMed ID: 36317532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
    N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
    Mukhtar H; Yasmeen U; Siddiqa S; Sarfraz Z; Sarfraz A
    Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Fox E; Lovett-Racke AE; Gormley M; Liu Y; Petracca M; Cocozza S; Shubin R; Wray S; Weiss MS; Bosco JA; Power SA; Mok K; Inglese M
    Mult Scler; 2021 Mar; 27(3):420-429. PubMed ID: 32351164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
    Boldrini VO; Mader S; Kümpfel T; Meinl E
    Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ublituximab: First Approval.
    Lee A
    Drugs; 2023 Apr; 83(5):455-459. PubMed ID: 36920653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review.
    Azhar A; Taimuri MA; Shamat SF; Ikram A; Ali S; Ali T; Khabir Y
    Ann Med Surg (Lond); 2023 Oct; 85(10):4909-4912. PubMed ID: 37811115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
    J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
    N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials.
    Xu M; Lu X; Fang J; Zhu X; Wang J
    J Clin Neurosci; 2016 Nov; 33():28-31. PubMed ID: 27492048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis.
    Costa GD; Comi G
    Expert Rev Neurother; 2023; 23(8):681-687. PubMed ID: 37382446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.